Home > Insider Trading > Filing (0001735276-21-000097)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1458494	Akshay Vaishnaw	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-21	5,417	$0.00	16,632	No	4	A	Direct
Common Stock	Disposition	2021-12-22	2,415	$189.13	14,217	No	4	F	Direct
Common Stock	Disposition	2021-12-22	1	$190.50	14,216	No	4	F	Direct
Common Stock	Disposition	2021-12-22	122	$186.48	14,094	No	4	F	Direct
Common Stock	Disposition	2021-12-23	124	$186.22	13,970	No	4	S	Direct
Common Stock	Disposition	2021-12-23	137	$187.08	13,833	No	4	S	Direct
Common Stock	Disposition	2021-12-23	130	$187.35	13,703	No	4	S	Direct
Common Stock	Disposition	2021-12-23	127	$188.26	13,576	No	4	S	Direct
Common Stock	Disposition	2021-12-23	73	$189.01	13,503	No	4	S	Direct
Common Stock	Disposition	2021-12-23	8	$189.18	13,495	No	4	S	Direct
Common Stock	Disposition	2021-12-23	144	$189.24	13,351	No	4	S	Direct
Common Stock	Disposition	2021-12-23	144	$190.02	13,207	No	4	S	Direct
Common Stock	Disposition	2021-12-23	5	$190.27	13,202	No	4	S	Direct
Common Stock	Disposition	2021-12-23	73	$190.33	13,129	No	4	S	Direct
Common Stock	Disposition	2021-12-23	142	$190.39	12,987	No	4	S	Direct
Common Stock	Disposition	2021-12-23	125	$190.86	12,862	No	4	S	Direct
Common Stock	Disposition	2021-12-23	1,000	$191.45	11,862	No	4	S	Direct
Common Stock	Disposition	2021-12-23	73	$192.25	11,789	No	4	S	Direct
Common Stock	Disposition	2021-12-23	126	$193.37	11,663	No	4	S	Direct
Common Stock	Disposition	2021-12-23	145	$193.67	11,518	No	4	S	Direct
Common Stock	Disposition	2021-12-23	303	$195.11	11,215	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	515	Indirect	by Managed Account

Footnotes

On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021.
Sale prices ranged from $191.14 to $191.80.
Sale prices ranged from $194.82 to $195.43.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.